Pfizer and UCL announce stem cell collaboration

Pfizer has announced that it has entered into a collaboration and license agreement with University College London focused on gaining better understanding into how to develop stem cell-based therapies for ophthalmic conditions. Under the terms of the agreement, Pfizer will provide funding to UCL to enable research into the development of stem cell-based therapies for AMD as well as other retinal diseases. Pfizer is granted exclusive worldwide rights to develop and commercialize an RPE stem cell-based therapeutic in the ophthalmology field. After the completion of preclinical safety studies, Pfizer will have the option to conduct clinical trials to determine efficacy of treatment and commercialize any resulting product.

About these ads